ライフサイエンスコーパス: phase I study

1 n were enrolled onto this single-institution phase I study.

2 antitumor activity were demonstrated in this phase I study.

3 nd gemcitabine has been evaluated in a prior phase I study.

4 therapy enrolled in this 28-day, open-label, phase I study.

5 /IV NSCLC were enrolled to this multicenter, phase I study.

6 previously entered at least one child into a phase I study.

7 d granulocyte-colony-stimulating factor in a phase I study.

8 Twenty-four patients were treated in the phase I study.

9 refractory solid tumors were enrolled onto a phase I study.

10 bstantial clinical activity was seen in this phase I study.

11 ified the process of dose escalation in this phase I study.

12 stinal graft-versus-host disease (GVHD) in a phase I study.

13 in a patient with ACC who was enrolled in a phase I study.

14 Eighteen patients are assessable on this phase I study.

15 an cancer patients that was noted during the phase I study.

16 ouble-blinded, placebo-controlled, crossover phase I study.

17 nitourinary (GU) tumors in a dose-escalation phase I study.

18 ion with pembrolizumab was investigated in a phase I study.

19 afe, well tolerated, and immunogenic in this phase I study.

20 center, randomized, double-blind, controlled phase I study.

21 maximum-tolerated dose derived in a previous phase I study.

22 ent glioblastoma multiforme (GBM) in a prior phase I study.

23 double-blind, randomised, placebo-controlled phase I studies.

24 or activity in taxane-refractory patients in phase I studies.

25 ncer treated in two ongoing, dose-escalating phase I studies.

26 ( P =.01 and.004, respectively) was seen in phase I studies.

27 UC, SUV, and Cmax were observed in tumors in phase I studies.

28 riguing clinical safety and efficacy data in phase I studies.

29 urther evidence for its poor efficacy in two phase I studies.

30 vanced non-small-cell lung cancer (NSCLC) in phase I studies.

31 l development, with the majority still being phase I studies.

32 and inflexible study designs of traditional Phase I studies.

33 mising candidate for evaluation in pediatric phase I studies.

34 e margin assessment, but data are limited to phase-I studies.

35 of FAPbI3 between the alpha-phase and delta-phase is studied.

36 In a phase I study, 12 patients with proliferative lupus neph

37 ulticenter, double-blind, placebo-controlled phase I study, 13 subjects were randomized to single-dos

38 Based on the phase I study, 525 mg/day is the recommended dose for or

39 In this phase I study, 90 patients with unresectable stage III o

40 We conducted a phase I study administering BMS-247550 as a 1-hour intra

41 In the phase I study, administration of TAK-062 was well tolera

42 This phase I study aimed to define the recommended phase II d

43 This phase I study aimed to describe the toxicity and to dete

44 The Global Asthma Network (GAN) Phase I study aimed to determine if the worldwide burden

45 citabine has shown some promising results in phase I studies and is being investigated in phase II tr

46 PH-797804 has met safety criteria in human phase I studies and is under clinical development for se

47 factors associated with multi-institutional phase I studies and OBD determination.

48 clinical toxicology, human pharmacokinetics, phase I studies, and activity against gastric carcinoma

49 lete and partial responses were seen in this phase I study, and clinical response appears related to

50 This first-in-human phase I study assessed safety, tolerability, pharmacokin

51 This phase I study assessed the safety, clinical feasibility,

52 This phase I study assessed the safety, optimally tolerated r

53 A phase I study assessed the safety, tolerability, pharmac

54 We performed a phase I study assessing the safety and clinical effects

55 ring for 15 years in patients from the START phase I study at Nationwide Children's Hospital in Colum

56 This phase I study attempted to report the initial safety and

57 e or a lot of pressure to participate in the phase I study because their cancer was growing, whereas

58 In phase I studies, brentuximab vedotin demonstrated signif

59 Patients are aware of many alternatives to phase I studies, but do not seriously consider them.

60 In this phase I study, capecitabine was administered twice daily

61 he Children's Cancer Group (CCG) undertook a phase I study (CCG-0922) to determine a tolerable dose o

62 In a phase I study, compound 1 eyedrops were well tolerated a

63 This review of completed phase I studies confirms the safety and generalizability

64 Phase I study data justify further clinical development

65 Conclusion: This phase I study defined the following two MTDs for clofara

66 This phase I study defined the MTD and recommended phase II d

67 Previous phase I studies demonstrated that a branched peptide con

68 This Phase I study demonstrated the feasibility, safety, and

69 This Phase I study demonstrated the feasibility, safety, and

70 This Phase I study demonstrated the feasibility, safety, and

71 This phase I study demonstrates that photoangioplasty with mo

72 The Phase I study described here represents the first gene t

73 The unique phase I study design allowed early identification of imp

74 sed therapy, three of whom were treated in a phase I study designed to establish the maximum tolerate

75 Patients were treated in a phase I study designed to establish the maximum-tolerate

76 This phase I study determined the maximum-tolerated dose (MTD

77 In a phase I study, devimistat (CPI-613) in combination with

78 Multi-institutional phase I studies do not decrease the time to study comple

79 made one of three decisions (enrollment on a phase I study, do not resuscitate status, or terminal ca

80 XPLORE (iExoKras(G12D) in Pancreatic Cancer) Phase I study employed a non-randomized single-arm class

81 This phase I study evaluated elacestrant, an investigational

82 This phase I study evaluated elotuzumab, lenalidomide, and de

83 This phase I study evaluated glofitamab in relapsed or refrac

84 This phase I study evaluated the maximum-tolerated dose (MTD)

85 This phase I study examined whether a heat shock protein (Hsp

86 This was a phase I study examining a once-weekly dosing schedule of

87 In phase I studies FAHF-2 was found to be safe and well tol

88 In pre-clinical and phase I studies, flurpiridaz F 18 has shown characterist

89 We have completed a phase I study, followed by three phase I/II studies, in

90 For the RRMS studies, an open-label phase I study found that rituximab reduced the annualize

91 In this phase I study, FP-21399 was administered intravenously o

92 Phase I studies have explored the safety and pharmacokin

93 Phase I studies have shown the dose-limiting toxicity to

94 Completed phase I studies have shown these combinations to be both

95 In this phase I study, HRG was administered intravenously as a s

96 This molecule successfully completed phase I studies in healthy adult volunteers and patients

97 Two Phase I studies in healthy human subjects evaluated safe

98 Phase I studies in pancreatic cancer (PDAC) utilizing P-

99 alysis of outcomes from select, single-agent phase I studies in patients with HGG.

100 linositol 3-kinase-delta, was evaluated in a phase I study in 64 patients with relapsed indolent non-

101 We conducted a phase I study in chemotherapy-naive patients with advanc

102 We constructed a phase I study in patients with locally advanced cervix c

103 controlled, sequential, rising multiple-dose phase I study in patients with moderate-to-severe psoria

104 Our institution conducted a phase I study in relapsed chronic lymphocytic leukemia.

105 m an open-label, dose-finding, seven-cohort, phase I study in which patients with symptomatic, multic

106 lticenter, double-blind, placebo-controlled, phase I study included adults who had been maintained on

107 Phase I studies indicated greater tolerability of lenali

108 Here we report the first-in-human phase I study investigating the maximum tolerated dose,

109 Moreover, data from a phase I study led to the FDA granting breakthrough thera

110 s with GPP who participated in a single-arm, phase I study (n = 7).

111 tion of BAY 1187982 in cancer patients and a phase I study (NCT02368951) has been initiated.

112 In this global, open-label, phase I study (NCT02517398), patients with programmed ce

113 e initiated a multi-institutional single-arm phase I study (NCT02599454) enrolling twenty patients wi

114 n-human, open-label, multicenter, three-part phase I study (NCT02783300) in patients with solid tumor

115 This phase I study (NCT03314181) evaluated venetoclax with da

116 This phase I study (NCT04840875) evaluated autologous CD7 CAR

117 the rabies glycoprotein, was evaluated in a Phase I study (NCT06048770).

118 In this phase I study, no significant toxicity was observed.

119 In phase I (studies of myocardial stunning), conscious rabb

120 In phase I (studies of myocardial stunning), rabbits were s

121 ly by an overall reduction in recruitment to phase I studies of 20%, more than half of whom would in

122 Phase I studies of antidepressants should incorporate ne

123 A criteria have routinely been enrolled onto phase I studies of antineoplastics without clinically me

124 monstrated efficacy and acceptable safety in phase I studies of heavily pretreated patients with HER2

125 dynamic biomarkers in cancer patients in two phase I studies of MLN8054, a small-molecule inhibitor o

126 Physicians involved in the conduct of phase I studies of novel anticancer agents have raised c

127 Both preclinical and human phase I studies of recombinant human endostatin (rhEndos

128 sistent with previously reported values from phase I studies of the drug given as a 24-hour IV infusi

129 Phase I studies of volunteers not infected with human im

130 aneously) on mast cells and melanocytes in a phase I study of 10 patients with advanced breast carcin

131 uccessful preclinical imaging, a prospective phase I study of 10 patients with multiple myeloma was p

132 We conducted a phase I study of 38 patients with solid tumors who faile

133 d radiation dose estimates of this tracer, a Phase I study of 62Cu-PTSM was performed using whole-bod

134 We conducted a phase I study of a 30-minute hepatic artery infusion of

135 We conducted a phase I study of a 7-day oral administration of PSC 833

136 We performed a phase I study of a day (D) 1 and D4 bortezomib administr

137 A phase I study of a pharmacokinetically derived schedule

138 ising results have been reported in an adult phase I study of ABT-510, a peptide derivative of the na

139 We conducted a phase I study of autologous T cells lentivirally-transdu

140 In a phase I study of cabozantinib, five of eight patients wi

141 Early observations of clinical benefit in a phase I study of cabozantinib, which included patients w

142 siency for this upregulation, we performed a phase I study of capecitabine in combination with weekly

143 We report a phase I study of cemiplimab for kidney transplant recipi

144 We conducted a first-in-humans phase I study of CTT1057 in patients with localized and

145 PATIENTS AND METHODS A phase I study of dasatinib in pediatric patients with re

146 A previously completed phase I study of devimistat in combination with cytarabi

147 mporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) le

148 patients with advanced melanoma treated in a phase I study of dose escalation of vemurafenib (PLX06-0

149 e skin and the skin of canines enrolled in a phase I study of F-PRT versus S-PRT.

150 We conducted a phase I study of flavopiridol, fludarabine, and rituxima

151 A phase I study of fresolimumab, a TGF-beta neutralizing a

152 n, showed promising efficacy and safety in a phase I study of heavily pretreated patients with KMT2A-

153 U31402-A-U102 is an ongoing phase I study of HER3-DXd in patients with advanced NSCL

154 minary antitumor efficacy were assessed in a phase I study of MK-0752.

155 We present a phase I study of N901-bR in relapsed SCLC.

156 A phase I study of navitoclax, a novel inhibitor of Bcl-2

157 Patients and Methods We performed a phase I study of oral Z-endoxifen to determine its toxic

158 titumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarc

159 A phase I study of patients with metastatic malignant mela

160 A phase I study of PEG-IFN with pharmacokinetic and pharma

161 In this phase I study of relapsed/refractory NHL, continuous inf

162 We conducted a phase I study of single-agent AZD1775 in adult patients

163 A phase I study of SIR-Spheres therapy with modified FOLFO

164 ies that required RT were enrolled onto this phase I study of standard chest radiation (30 daily 2-Gy

165 This phase I study of the Innovative Therapies for Children w

166 These findings led to the present phase I study of the intravenous infusion of VNP20009 to

167 ation therapy (PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and

168 In March 2006, a phase I study of the superagonistic anti-CD28 antibody T

169 y subcutaneous (SC) injections of rhSCF in a phase I study of this cytokine.

170 CC-90010-ST-001 is an open-label phase I study of trotabresib, an oral BET inhibitor, in

171 edly with prolonged exposure, we performed a phase I study of weekly XR5000 by 120-hour continuous in

172 Here, we report the results of a phase I study of WT2725.

173 We conducted initial (Phase I) studies of acute safety and efficacy of aerosol

174 We report results from a first-in-human phase-I study of fianlimab and cemiplimab safety and eff

175 or currently under investigation in multiple phase I studies on various malignancies, and its clincal

176 ated clinically relevant improvement in this phase I study on this small group of patients with activ

177 py Evaluation Program-sponsored single-agent phase I studies over three decades (1979 to 2010).

178 This open-labeled phase I study provides the first demonstration of the im

179 A phase I study recently reported that seviteronel, a CYP1

180 1.46 L x min(-1) x m(-2) in pre-phase I and phase I studies, respectively) with the production of se

181 Phase I study results for ABT-510, which inhibits angiog

182 Eleven patients were entered onto the phase I study: seven with AML, three with acute lymphobl

183 Phase I study showed that intraventricular rituximab plu

184 KEY POINTS: Phase I study showed that intraventricular rituximab plu

185 Preclinical and phase I studies showing efficacy of antiinsulin-like gro

186 erable than twice-weekly dosages used in the phase I study, so 3 ug/kg every 2 weeks was the phase II

187 This phase I study sought to determine the safety and antitum

188 This phase I study sought to determine the safety and tolerab

189 bial activity, and clinical response in this Phase I study suggest that this tetracycline-containing

190 Patients and Methods This phase I study tested durvalumab doublets in parallel 3 +

191 Patients and Methods This phase I study tested the combination of M6620 and topote

192 We conducted a phase I study that examined the biodistribution of (131)

193 Based on results from a phase I study that showed T-DM1 was well tolerated at th

194 A total of 47 patients were treated in the phase I study that used a classical 3 + 3 design.

195 In the phase I study, the dose-limiting toxicities were hand-fo

196 In our phase I study, the intravenous formulation of irinotecan

197 In this Phase I study, the maximally tolerated doses (MTDs) of i

198 In a phase I study, the maximum tolerated dose of AZD1775 in

199 In this phase I study, the maximum-tolerated dose (MTD) and safe

200 itide 3-kinase-delta,-gamma, in RR iNHL in a phase I study, the safety and efficacy of duvelisib mono

201 cademia often partner for the performance of phase I studies, their administrative processes are gene

202 We performed a phase I study to determine the appropriate dose of PN401

203 conducted a first-in-man (to our knowledge) phase I study to determine the dose-limiting toxicities

204 Phase I study to determine the maximum tolerated dose (M

205 We conducted a phase I study to determine the maximum-tolerated dose (M

206 This was a phase I study to determine the maximum-tolerated dose (M

207 We conducted a phase I study to determine the maximum-tolerated dose an

208 We conducted a phase I study to evaluate the safety and immunologic act

209 These studies support the initiation of a phase I study to evaluate the safety and potential effic

210 We conducted a phase I study to investigate the feasibility and safety

211 armacokinetic data derived from our clinical phase I study to set parameter values.

212 This phase I study used radiolabeled huA33 in combination wit

213 A phase I study using anti-BlyS in SLE demonstrated a sele

214 A phase I study using the nonimmunosuppressive MDR1 blocke

215 The phase I study was aimed at evaluating the safety, biodis

216 The most common toxicity in the phase I study was anemia, seen in 66% of patients.

217 A multicenter, open-label, repeated-dose, phase I study was conducted to assess the safety, tolera

218 A phase I study was conducted to determine the maximum-tol

219 This phase I study was conducted to determine the recommended

220 This phase I study was conducted to determine the toxicities,

221 A phase I study was conducted to determine the toxicity, p

222 This phase I study was designed to define the maximum-tolerat

223 This phase I study was designed to evaluate the safety, pharm

224 This phase I study was designed to evaluate the safety, toler

225 The present phase I study was devised to determine the toxicity, pha

226 The phase I study was extended to a limited phase II study t

227 This phase I study was initiated to determine the toxicity an

228 A phase I study was performed to determine the maximum-tol

229 This phase I study was performed to evaluate the safety and p

230 A phase I study was performed to evaluate the safety, in v

231 The primary goal of this Phase I study was to assess the safety and bioactivity o

232 The purpose of this phase I study was to define the safety and efficacy of b

233 The goal of this phase I study was to determine the maximum tolerated dos

234 The aim of this phase I study was to determine the safety and toxicity p

235 Our objective in this phase I study was to determine the tolerability of pacli

236 The aim of the present phase I study was to evaluate the biodistribution and do

237 The purpose of this phase I study was to evaluate the safety and immunogenic

238 This phase I study was undertaken to define the toxicity, pha

239 (collected through gastric aspiration in the phase I study) was quantified using R5 and G12 monoclona

240 In addition to the diarrhea observed in phase I studies, we also observed a higher incidence of

241 afenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study

242 Two phase I studies were conducted of ABR-217620 alone or in

243 Serum levels of flavopiridol obtained during phase I studies were sufficient to inhibit in vitro canc

244 The goals of this phase I study were to determine the maximum-tolerated do

245 The objectives of this phase I study were to evaluate radiation dosimetry, biod

246 The aims of this phase I study were to investigate (68)Ga-SB3 PET/CT imag

247 inal illnesses who enroll as participants in phase I studies, which assess the toxicity and dosing of

248 This phase I study, which to our knowledge is the first-in-hu

249 Phase I studies with JNJ-9117 have been initiated in hea

250 teria may be good candidates for solid tumor phase I studies with single-agent molecular or cytotoxic

251 We conducted a randomized phase I study with 148 healthy volunteers (HV) to test t

252 ates for chemotherapy, were included in this phase I study with a 3 + 3 dose escalation design.

253 carcinoma (RCC) treated with nivolumab in a phase I study with expansion cohorts.

254 Our phase I study with recombinant HCV E1/E2 envelope glycop

255 in vitro and in healthy participants in the phase I study, with and without pretreatment with a prot

256 ificantly decrease the duration of pediatric phase I studies without increasing the risk of toxicity.